×

Learn more

First Name
Last Name
Company Name
Country
State
Province
State
Region
State
Canton
Yes, keep me updated about NanoTemper
By checking this box, you provide us consent to email you educational content, and information on our products, services and events. You may unsubscribe at any time.
Agree to Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.
Thank you!
Error - something went wrong!

Integrated fragment-based approach reveals enzymatic inhibitors w/ potential therapeutic application

Indoleamine 2,3 dioxygenase 1 (IDO1) is an heme-containing enzyme that catalyses the conversion of L-Tryptophan (Trp) into a series of bioactive metabolites along the kynurenine pathway, eventually leading to immunoregulatory effects. These effects include induction of regulatory T-cell differentiation and activation, suppression of T-cell immune responses and inhibition of dendritic cell function.

On this basis, IDO1 is widely recognised as a valuable drug target for the development of immunotherapeutic small molecules in oncology. Although numerous chemical classes of potent IDO1 inhibitors that have been discovered, few compounds have progressed in clinical trials, while the most advanced drug candidate (Epacadostat) has unfortunately failed in phase III clinical trials in metastatic melanoma patients.

These disappointing results highlight the complexity of targeting IDO1 for drug discovery, and perhaps suggest a still elusive knowledge on its biological functions. Accordingly, next generation ligands are sought with the aim of investigating hidden and relevant aspects of IDO1 biology.

In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme. They focused on MicroScale Thermophoresis (MST) as the cornerstone methodology of their discovery pipeline and concluded with an outlook on the impact of fragment-based approaches in the drug discovery of the post-genomic era.

Previous Video
Unlock your prometheus: Exploring successful workflows
Unlock your prometheus: Exploring successful workflows

Next Video
Developability assessment of therapeutic proteins – a toolbox for tackling increasing complexity
Developability assessment of therapeutic proteins – a toolbox for tackling increasing complexity

Early lead selection of biotherapeutics during preclinical development requires careful characterization of...

Have a question?

Contact Specialist